Lv63
2480 积分 2023-05-24 加入
The PARP inhibitor/Immunotherapy Paradox in Advanced Ovarian Cancer: Positive Endpoints, Perplexing Interpretations
4小时前
求助中
Intratumoral heterogeneity and immunotherapy resistance: clinical implications
4小时前
已完结
Real-World Guide for Delivering Immunotherapy With Radiation Therapy
6小时前
已完结
5-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiotherapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma
2天前
已完结
Stage IA3 Endometrial Cancer in the FIGO 2023 Classification: A Case of Clarity or Complexity?
2天前
已完结
Stage IA3 endometrial cancer in the FIGO 2023 classification: a case of clarity or complexity?
9天前
已关闭
5-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiotherapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma
9天前
已关闭
5-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiotherapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma
13天前
已关闭
Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008
1个月前
已完结
Defining the heterogeneity of endometrial clear cell carcinomas: evaluation of molecular and histologic predictors of prognosis
1个月前
已关闭
皖公网安备34019202002308
